Breaking News

Financial Reports: Biogen Idec

April 25, 2013

MS franchise continues growth

Biogen Idec 1Q13

1Q Revenues: $1.4 billion (+10%)

1Q Earnings: $427 million (+41%)

Comments: Avonex sales rose 13% ($746 million), Tysabri rose 9% ($312 million), Fampyra was up 54% ($23 million) and Fumaderm was up 8% ($14 million). Rituxan revenues from its joint business arrangement fell 7% to $265 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks